Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance

Sensory hypersensitivities are common and distressing features of Fragile X Syndrome (FXS). While there are many drug interventions that reduce behavioral deficits in Fmr1 mice and efforts to translate these preclinical breakthroughs into clinical trials for FXS, evidence-based clinical intervention...

Full description

Bibliographic Details
Main Authors: Lauren E. Ethridge, Lisa A. De Stefano, Lauren M. Schmitt, Nicholas E. Woodruff, Kara L. Brown, Morgan Tran, Jun Wang, Ernest V. Pedapati, Craig A. Erickson, John A. Sweeney
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Integrative Neuroscience
Subjects:
EEG
Online Access:https://www.frontiersin.org/article/10.3389/fnint.2019.00060/full
id doaj-01d6d9834fcf4d7eb051f96ef9111b4e
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Lauren E. Ethridge
Lauren E. Ethridge
Lisa A. De Stefano
Lauren M. Schmitt
Lauren M. Schmitt
Nicholas E. Woodruff
Kara L. Brown
Morgan Tran
Jun Wang
Ernest V. Pedapati
Ernest V. Pedapati
Ernest V. Pedapati
Craig A. Erickson
Craig A. Erickson
John A. Sweeney
spellingShingle Lauren E. Ethridge
Lauren E. Ethridge
Lisa A. De Stefano
Lauren M. Schmitt
Lauren M. Schmitt
Nicholas E. Woodruff
Kara L. Brown
Morgan Tran
Jun Wang
Ernest V. Pedapati
Ernest V. Pedapati
Ernest V. Pedapati
Craig A. Erickson
Craig A. Erickson
John A. Sweeney
Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance
Frontiers in Integrative Neuroscience
Fragile X Syndrome
EEG
chirp
habituation
gamma
sensory
author_facet Lauren E. Ethridge
Lauren E. Ethridge
Lisa A. De Stefano
Lauren M. Schmitt
Lauren M. Schmitt
Nicholas E. Woodruff
Kara L. Brown
Morgan Tran
Jun Wang
Ernest V. Pedapati
Ernest V. Pedapati
Ernest V. Pedapati
Craig A. Erickson
Craig A. Erickson
John A. Sweeney
author_sort Lauren E. Ethridge
title Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance
title_short Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance
title_full Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance
title_fullStr Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance
title_full_unstemmed Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance
title_sort auditory eeg biomarkers in fragile x syndrome: clinical relevance
publisher Frontiers Media S.A.
series Frontiers in Integrative Neuroscience
issn 1662-5145
publishDate 2019-10-01
description Sensory hypersensitivities are common and distressing features of Fragile X Syndrome (FXS). While there are many drug interventions that reduce behavioral deficits in Fmr1 mice and efforts to translate these preclinical breakthroughs into clinical trials for FXS, evidence-based clinical interventions are almost non-existent potentially due to lack of valid neural biomarkers. Local circuit function in sensory networks is dependent on the dynamic balance of activity in inhibitory/excitatory synapses. Studies are needed to examine the association of electrophysiological alterations in neural systems with sensory and other clinical features of FXS to establish their clinical relevance. Adolescents and adults with FXS (n = 38, Mean age = 25.5, std = 10.1; 13 females) and age matched typically developing controls (n = 40, Mean age = 27.7, std = 12.1; 17 females) completed auditory chirp and auditory habituation tasks while undergoing dense array electroencephalography (EEG). Amplitude, latency, and percent change (habituation) in N1 and P2 event-related potential (ERP) components were characterized for the habituation task; time-frequency calculations using Morlet wavelets characterized phase-locking and single trial power for the habituation and chirp tasks. FXS patients showed increased amplitude but some evidence for reduced habituation of the N1 ERP, and reduced phase-locking in the low and high gamma frequency range and increased low gamma power to the chirp stimulus. FXS showed increased theta power in both tasks. While the habituation finding was weaker than previously found, the remaining findings replicate our previous work in a new sample of patients with FXS. Females showed less deficit in the chirp task but not the habituation task. Abnormal increases in gamma power were related to more severe behavioral and psychiatric features as well as reductions in neurocognitive abilities. Replicating electrophysiological deficits in a new group of patients using different EEG equipment at a new data collection site with differing levels of environmental noise that were robust to data processing techniques utilizing multiple researchers, indicates a potential for scalability to multi-site clinical trials. Given the robust replicability, relevance to clinical measures, and preclinical evidence for sensitivity of these EEG measures to pharmacological intervention, the observed abnormalities may provide novel translational markers of target engagement and potentially outcome measures in large-scale studies evaluating new treatments targeting neural hyperexcitability in FXS.
topic Fragile X Syndrome
EEG
chirp
habituation
gamma
sensory
url https://www.frontiersin.org/article/10.3389/fnint.2019.00060/full
work_keys_str_mv AT laureneethridge auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT laureneethridge auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT lisaadestefano auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT laurenmschmitt auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT laurenmschmitt auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT nicholasewoodruff auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT karalbrown auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT morgantran auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT junwang auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT ernestvpedapati auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT ernestvpedapati auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT ernestvpedapati auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT craigaerickson auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT craigaerickson auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
AT johnasweeney auditoryeegbiomarkersinfragilexsyndromeclinicalrelevance
_version_ 1725900692034420736
spelling doaj-01d6d9834fcf4d7eb051f96ef9111b4e2020-11-24T21:46:41ZengFrontiers Media S.A.Frontiers in Integrative Neuroscience1662-51452019-10-011310.3389/fnint.2019.00060460467Auditory EEG Biomarkers in Fragile X Syndrome: Clinical RelevanceLauren E. Ethridge0Lauren E. Ethridge1Lisa A. De Stefano2Lauren M. Schmitt3Lauren M. Schmitt4Nicholas E. Woodruff5Kara L. Brown6Morgan Tran7Jun Wang8Ernest V. Pedapati9Ernest V. Pedapati10Ernest V. Pedapati11Craig A. Erickson12Craig A. Erickson13John A. Sweeney14Department of Pediatrics, Section of Developmental and Behavioral Pediatrics, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesDepartment of Psychology, The University of Oklahoma, Norman, OK, United StatesDepartment of Psychology, The University of Oklahoma, Norman, OK, United StatesDivision of Developmental and Behavioral Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United StatesDepartment of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, United StatesDepartment of Psychology, The University of Oklahoma, Norman, OK, United StatesDepartment of Psychology, The University of Oklahoma, Norman, OK, United StatesDepartment of Psychology, The University of Oklahoma, Norman, OK, United StatesDepartment of Psychology, Zhejiang Normal University, Jinhua, ChinaDepartment of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, United StatesDivision of Child and Adolescent Psychiatry, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United StatesDivision of Child Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United StatesDepartment of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, United StatesDivision of Child and Adolescent Psychiatry, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United StatesDepartment of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, United StatesSensory hypersensitivities are common and distressing features of Fragile X Syndrome (FXS). While there are many drug interventions that reduce behavioral deficits in Fmr1 mice and efforts to translate these preclinical breakthroughs into clinical trials for FXS, evidence-based clinical interventions are almost non-existent potentially due to lack of valid neural biomarkers. Local circuit function in sensory networks is dependent on the dynamic balance of activity in inhibitory/excitatory synapses. Studies are needed to examine the association of electrophysiological alterations in neural systems with sensory and other clinical features of FXS to establish their clinical relevance. Adolescents and adults with FXS (n = 38, Mean age = 25.5, std = 10.1; 13 females) and age matched typically developing controls (n = 40, Mean age = 27.7, std = 12.1; 17 females) completed auditory chirp and auditory habituation tasks while undergoing dense array electroencephalography (EEG). Amplitude, latency, and percent change (habituation) in N1 and P2 event-related potential (ERP) components were characterized for the habituation task; time-frequency calculations using Morlet wavelets characterized phase-locking and single trial power for the habituation and chirp tasks. FXS patients showed increased amplitude but some evidence for reduced habituation of the N1 ERP, and reduced phase-locking in the low and high gamma frequency range and increased low gamma power to the chirp stimulus. FXS showed increased theta power in both tasks. While the habituation finding was weaker than previously found, the remaining findings replicate our previous work in a new sample of patients with FXS. Females showed less deficit in the chirp task but not the habituation task. Abnormal increases in gamma power were related to more severe behavioral and psychiatric features as well as reductions in neurocognitive abilities. Replicating electrophysiological deficits in a new group of patients using different EEG equipment at a new data collection site with differing levels of environmental noise that were robust to data processing techniques utilizing multiple researchers, indicates a potential for scalability to multi-site clinical trials. Given the robust replicability, relevance to clinical measures, and preclinical evidence for sensitivity of these EEG measures to pharmacological intervention, the observed abnormalities may provide novel translational markers of target engagement and potentially outcome measures in large-scale studies evaluating new treatments targeting neural hyperexcitability in FXS.https://www.frontiersin.org/article/10.3389/fnint.2019.00060/fullFragile X SyndromeEEGchirphabituationgammasensory